Business deal

Janssen Announces Promising Antiviral Activity Against Dengue in a Phase 2a Human Challenge Model

By October 26, 2023September 10th, 2026No Comments1 min read

Janssen shared Phase 2a data of our Dengue antiviral. Good news: JNJ-1802 induced antiviral activity against dengue virus in humans!

 

More information can be found in the J&J Press Release.

Read the press release

Related Posts

Business deal Promising antiviral drug candidate against dengue gets new opportunity for further development

Promising antiviral drug candidate against dengue gets new opportunity for further development

Jan De Rijck
Jan De RijckOctober 19, 2026
Business deal CD3 announces investment in Enedra Therapeutics to advance drug discovery programmes from its proprietary CASPAROV platform for difficult to treat cancers

CD3 announces investment in Enedra Therapeutics to advance drug discovery programmes from its proprietary CASPAROV platform for difficult to treat cancers

Sven_CD3
Sven_CD3May 6, 2025
Business deal KU Leuven joins EndLyz Therapeutics’ fight against Parkinson’s disease

KU Leuven joins EndLyz Therapeutics’ fight against Parkinson’s disease

Sven_CD3
Sven_CD3April 10, 2025
Share